Biomarker IP after Prometheus: Patenting the Unpatentable
Conference Recording Feb 10, 2014
About the SpeakerDr. Scott is a patent attorney at Klarquist Sparkman, LLP in Portland, Oregon, where he prepares and prosecutes U.S. and International patent applications, and advises clients about patent portfolio management, freedom-to-operate, and strategic product development. His technical experience includes applications related to biochemistry, molecular genetics, virology, immunology, and neurobiology. Dr. Scott’s practice emphasis is in biotechnology, including applications relating to biologic drugs and their use, and diagnostic methods involving exosome and DNA expression profiling. Dr. Bradley is a partner at Klarquist Sparkman, LLP in Portland, Oregon. She specializes in the preparation and prosecution of U.S. and International patent applications, and advises clients about patent portfolio management, freedom-to-operate, and strategic product development. Her practice emphasis is on preparing medical, chemical, biotechnical, and pharmaceutical patent applications, including applications relating to biologic drugs and their use, and diagnostic methods involving DNA expression profiling. Dr. Bradley has a strong multidisciplinary background with technical expertise in molecular biology, cell biology, structural biology, physiology, and pharmacology.
AbstractIn this tag-team presentation, two IP lawyers will discuss the latest trends in this evolving field:
The Supreme Court decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc. shifted the biomarker IP landscape by raising the bar to obtain meaningful patent protection for diagnostic methods involving biomarker detection. We will review recent developments in patent law concerning diagnostic method claims, and the approaches we are currently using to successfully address the Prometheus standard.
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018